Literature DB >> 28470571

Immunohistochemical Analysis of the Expression of Breast Markers in Basal-like Breast Carcinomas Defined as Triple Negative Cancers Expressing Keratin 5.

Tamás Zombori1, Gábor Cserni2,3.   

Abstract

Estrogen and progesterone receptors are possible markers for suggesting a mammary origin of metastatic carcinoma, but are useless in cases of triple negative breast cancers (TNBC). Five other potential markers of breast origin were investigated on tissue microarrays in a series of TNBCs showing keratin 5 expression, consistent with a basal-like phenotype. GATA-3 staining was observed in 82 of 115 triple negative cases (71.3%) including 23 cases with >5% staining. Mammaglobin staining was detected in 30 cases (26.0%) including 12 with >5% staining. GCDFP-15 was seen in 23 cases (20.0%) including 9 with >5% staining. NY-BR-1 positivity was present in 7 cases (6.0%) including 3 patients with >5% staining. BCA-225 staining was observed in 74 cases (64.3%); however this latter marker lacks also specificity owing to the reported widespread staining in other malignancies. GATA-3, mammaglobin and GCDFP-15 coexpression was seen in one case (0.9%), whereas GATA-3 and mammaglobin or mammaglobin and GCDFP-15 coexpression was present in 2 and 2 cases (1.7%), respectively. Using at least 5% staining as cut-off, the expression of any of the last 4 markers was 34.7%. The expression of GATA-3, mammaglobin, GCDFP-15 and NY-BR-1 is lower in TNBC-s than in breast carcinomas in general, and this may be even lower in basal-like carcinomas. Although these markers are not fully specific, by using them, a subset of basal-like TNBC-s can be identified as of mammary origin. However, a substantial proportion will not show any staining with any of these markers.

Entities:  

Keywords:  Basal-like; GATA-3; GCDFP-15; Mammaglobin; NY-BR-1; Triple negative breast cancer

Mesh:

Substances:

Year:  2017        PMID: 28470571     DOI: 10.1007/s12253-017-0246-y

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  61 in total

1.  GATA3 immunohistochemistry expression in histologic subtypes of primary breast carcinoma and metastatic breast carcinoma cytology.

Authors:  Georgios Deftereos; Angela M Sanguino Ramirez; Jan F Silverman; Uma Krishnamurti
Journal:  Am J Surg Pathol       Date:  2015-09       Impact factor: 6.394

2.  Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions.

Authors:  Madelyn Lew; Judy C Pang; Xin Jing; Kristina L Fields; Michael H Roh
Journal:  Cancer Cytopathol       Date:  2015-10       Impact factor: 5.284

3.  Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity.

Authors:  Rohit Bhargava; Sushil Beriwal; David J Dabbs
Journal:  Am J Clin Pathol       Date:  2007-01       Impact factor: 2.493

4.  Semiquantitative GATA-3 immunoreactivity in breast, bladder, gynecologic tract, and other cytokeratin 7-positive carcinomas.

Authors:  Beth Z Clark; Surabhi Beriwal; David J Dabbs; Rohit Bhargava
Journal:  Am J Clin Pathol       Date:  2014-07       Impact factor: 2.493

5.  GATA-3 expression as a predictor of hormone response in breast cancer.

Authors:  Purvi Parikh; Juan P Palazzo; Lewis J Rose; Constantine Daskalakis; Ronald J Weigel
Journal:  J Am Coll Surg       Date:  2005-05       Impact factor: 6.113

6.  The differentiation antigen NY-BR-1 is a potential target for antibody-based therapies in breast cancer.

Authors:  Inka Seil; Claudia Frei; Holger Sültmann; Shirley K Knauer; Knut Engels; Elke Jäger; Kurt Zatloukal; Michael Pfreundschuh; Alexander Knuth; Yao Tseng-Chen; Achim A Jungbluth; Roland H Stauber; Dirk Jäger
Journal:  Int J Cancer       Date:  2007-06-15       Impact factor: 7.396

7.  Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study.

Authors:  Nelson G Ordóñez; Aysegul A Sahin
Journal:  Hum Pathol       Date:  2014-03-27       Impact factor: 3.466

8.  GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas.

Authors:  Ashley Cimino-Mathews; Andrea P Subhawong; Peter B Illei; Rajni Sharma; Marc K Halushka; Russell Vang; John H Fetting; Ben Ho Park; Pedram Argani
Journal:  Hum Pathol       Date:  2013-01-31       Impact factor: 3.466

9.  Differential immunostaining of various types of breast carcinomas for growth hormone-releasing hormone receptor - Apocrine epithelium and carcinomas emerging as uniformly positive.

Authors:  Bence Kővári; Orsolya Rusz; Andrew V Schally; Zsuzsanna Kahán; Gábor Cserni
Journal:  APMIS       Date:  2014-01-31       Impact factor: 3.205

10.  GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors.

Authors:  Markku Miettinen; Peter A McCue; Maarit Sarlomo-Rikala; Janusz Rys; Piotr Czapiewski; Krzysztof Wazny; Renata Langfort; Piotr Waloszczyk; Wojciech Biernat; Jerzy Lasota; Zengfeng Wang
Journal:  Am J Surg Pathol       Date:  2014-01       Impact factor: 6.394

View more
  4 in total

1.  Transcriptomic analysis to affirm the regulatory role of long non-coding RNA in horn cancer of Indian zebu cattle breed Kankrej (Bos indicus).

Authors:  Pritesh H Sabara; Subhash J Jakhesara; Ketankumar J Panchal; Chaitanya G Joshi; Prakash G Koringa
Journal:  Funct Integr Genomics       Date:  2019-07-31       Impact factor: 3.410

2.  Integrated Bioinformatics Data Analysis Reveals Prognostic Significance Of SIDT1 In Triple-Negative Breast Cancer.

Authors:  Ya Wang; Hanning Li; Jingjing Ma; Tian Fang; Xiaoting Li; Jiahao Liu; Henok Kessete Afewerky; Xiong Li; Qinglei Gao
Journal:  Onco Targets Ther       Date:  2019-10-11       Impact factor: 4.147

3.  Syntaxin-1 and Insulinoma-Associated Protein 1 Expression in Breast Neoplasms with Neuroendocrine Features.

Authors:  Sándor Turkevi-Nagy; Ágnes Báthori; János Böcz; László Krenács; Gábor Cserni; Bence Kővári
Journal:  Pathol Oncol Res       Date:  2021-10-26       Impact factor: 3.201

4.  Verification and Validation of a Four-Gene Panel as a Prognostic Indicator in Triple Negative Breast Cancer.

Authors:  Mamta Pariyar; Rick F Thorne; Rodney J Scott; Kelly A Avery-Kiejda
Journal:  Front Oncol       Date:  2022-03-21       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.